Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

5
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
5
Competition02:34

Competition

22.8K
When organisms require the same limited resources within an environment, they may have to compete for them. Competition is a net-negative interaction. Even if two competing individuals or populations do not interact directly, the overall fitness of both competitors is lowered as a result of not having full access to the limited resource.
22.8K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.3K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

11
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
11
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

11
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
11
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

10
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
10

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physician Antibiotic Prescribing Preferences in Community Acquired Pneumonia and Complicated Urinary Tract Infections: A National Discrete Choice Experiment.

Open forum infectious diseases·2026
Same author

The Pharmaceutical Industry's Quiet Win in the One Big Beautiful Bill Act.

Annals of internal medicine·2025
Same author

Health Affairs Scholar expands its reach with fast-tracked peer review and new article formats to meet today's needs.

Health affairs scholar·2025
Same author

The changing landscape of primary care: an analysis of payer-primary care integration.

Health affairs scholar·2025
Same author

The comparative effectiveness and safety of fluticasone-salmeterol via metered-dose versus dry powder inhalers for COPD: A new user cohort study.

PLoS medicine·2025
Same author

Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2025
Same journal

Health on the Move: The Impact of Poverty Alleviation Relocation on Healthcare Utilization in China.

Health economics·2026
Same journal

The Effects of Compulsory Licensing: A Case Study of HIV Drugs.

Health economics·2026
Same journal

Beyond Tobacco Prevention: The Effects of Tobacco 21 Laws on Young Adults' Body Weight.

Health economics·2026
Same journal

Assessing the Estimands and Estimates of Hospitalization Rates in Health Economics and Clinical Medicine.

Health economics·2026
Same journal

The Impact of Unemployment Insurance Benefit Cuts on Mental Health: Evidence From Early Pandemic Program Expirations.

Health economics·2026
Same journal

Do Patients Value the Service Provided by Physicians Who Overbill? A Willingness-to-Pay Study Using French Survey Data.

Health economics·2026
See all related articles

Related Experiment Video

Updated: Oct 6, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K

Biosimilar competition: Early learning.

Richard G Frank1, Mahnum Shahzad2, Aaron S Kesselheim3

  • 1The Brookings Institution, Washington, District of Columbia, USA.

Health Economics
|January 13, 2022
PubMed
Summary
This summary is machine-generated.

Biosimilar competition, spurred by the Biological Price Competition and Innovation Act (BPCIA), has begun to lower biologic drug prices. Each new biosimilar entrant reduces prices, though not as much as initially anticipated.

Keywords:
biosimilarcompetitionprices

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.8K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.3K

Related Experiment Videos

Last Updated: Oct 6, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.8K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.3K

Area of Science:

  • Pharmaceutical Economics
  • Health Policy
  • Drug Pricing

Background:

  • Biologics represent a significant and rapidly growing sector of the pharmaceutical market, with substantial healthcare spending.
  • The Biological Price Competition and Innovation Act (BPCIA) of 2010 aimed to foster competition and reduce costs through biosimilar pathways.
  • Initial expectations for significant price moderation following the BPCIA have not been fully realized.

Purpose of the Study:

  • To investigate the early effects of biosimilar competition on the utilization and pricing of biologic products.
  • To analyze how market structure changes, influenced by the BPCIA, impact biologic drug prices.
  • To quantify the price reductions associated with biosimilar market entry.

Main Methods:

  • Analysis of seven biologic products that have recently experienced biosimilar competition.
  • Estimation of fixed effects and Instrumental Variables models to assess the relationship between market competition and prices.
  • Focus on changes in market structure and their impact on pricing dynamics.

Main Results:

  • Each additional marketed product, specifically biosimilars, leads to a weighted average market price reduction of 5.4% to 7%.
  • This price moderation is attributed to both reduced originator prices and a shift in consumer demand towards biosimilar alternatives.
  • The observed impact suggests a tangible, albeit moderate, effect of biosimilar competition on biologic pricing.

Conclusions:

  • Biosimilar competition, facilitated by the BPCIA, is contributing to lower biologic drug prices.
  • The market entry of biosimilars demonstrates a measurable impact on originator pricing and consumer choice.
  • Further monitoring is warranted to fully understand the long-term economic implications of biosimilar adoption.